1.    Regulation of IFN-g (STAT-1) signal transduction. Targeting diseases: inflammation, leucopenia, and cancer. A cell-based gene promoter-reporter assay for identification of regulators of IFN-g (STAT-1) signaling pathway.  This is a cell line specifically designed and developed to monitor both stimulating phase and declining phase of the signal.  It is also used to identify both inhibitors and enhancers of the pathway.  The pathway inhibitors will be used for treating inflammation.  The uniqueness of this screening assay is its ability to identify enhancers of the pathway, which are novel type drug candidates that can be used on their own or in combination with IFN-g to boost immune response to fight cancer and viral infection. 2.  Regulation of IL-6 (STAT-3) signal transduction. Targeting diseases: inflammation, leucopenia, and cancer. A cell-based gene promoter-reporter assay for identification of regulators of IL-6 (STAT-3) signaling pathway.  This is a cell line specifically designed and developed to monitor both stimulating phase and declining phase of the signal.  It is also used to identify both inhibitors and enhancers of the pathway.  The pathway inhibitors will be used for treating inflammation and cancer.  3. Regulation of IFN-a (STATs) signal transduction. Targeting diseases: hepatitis, inflammation, and cancer. A cell-based gene promoter-reporter assay for identification of regulators of IFN-a (STATs) signaling pathway.  This is a cell line specifically designed and developed to monitor both stimulating phase and declining phase of the signal.  It is also used to identify both inhibitors and enhancers of the pathway.  The enhancers of the pathway are novel type drug candidates that can be used on their own or in combination with IFN-a to boost immune response to fight cancer and viral infection. 4.  Regulation of TNF-a (NF-kB) signal transduction. Targeting diseases: inflammation and cancer. A cell-based gene promoter-reporter assay for identification of regulators of TNF-a (NF-kB) signaling pathway.  This is a cell line specifically designed and developed to monitor both stimulating phase and declining phase of the signal.  It is therefore used to identify both inhibitors and enhancers of the pathway.  The pathway inhibitors will be used for treating inflammation.  The pathway enhancers are novel type drug candidates that can be used on their own or in combination with TNF-a to boost immune response to fight cancer and viral infection. 5.  Regulation of tyrosine kinase signal transduction. Targeting disease: cancer. A cell-based gene promoter-reporter assay for identification of regulators of cell surface receptor tyrosine kinase-mediated signaling pathway.  This is a cell line specifically designed and developed to monitor both stimulating phase and declining phase of the signal.  It is also used to identify both inhibitors and enhancers of the pathway. 6.  Regulation of WNT signal transduction. Targeting disease: cancer. A cell-based gene promoter-reporter assay for identification of regulators of WNT signaling pathway.  7.  Regulation of tumor cell anchorage-independent growth. Targeting disease: cancer. A cell-based gene promoter-reporter assay for identification of regulators of cell anchorage signaling pathway.  This promoter-reporter gene is regulated by cell-cell and cell-matrix interaction. 8.Regulation of Mitosis. Targeting disease: cancer. A cell-based assay for identification of mitosis inhibitors.  The uniqueness of this assay is that it is designed to identify mitosis inhibitors that do not affect microtubules.  These inhibitors will be used on their or in combination with microtubule inhibitors to treat cancer. 9.Regulation of ER-stress-induced cell death. Targeting disease: viral infection. A cell-based assay for identification of inhibitors of ER-stress-induced cell death.  This assay is based on the phenomenon that all viruses use host cells protein synthesis machinery to synthesize their own proteins, which cause ER-stress and induce host cell death.  Inhibition of ER-stress-induced cell death will protect host cells from virus-induced death.  The potential use of this type of inhibitors is to treat acute lethal viral infection.  10. Regulation of autophagy. Targeting disease: cancer, inflammation, viral infection. A cell-based assay for identification of inhibitors or enhancers of autophagy.  Cell autophagy is a fundamental cellular process whose disregulation is involved in variety human diseases, particularly cancer.  The potential uses of these regulators are to treat cancer and inflammation. Animal models: 1.Syngeneic mouse cancer model. This is a mouse S180 sarcoma cell xenograft model.  It is used to exam in vivo anti-tumor growth activity of a candidate drug. 2.Nude Mice xenograft cancer model. This is a mouse human tumor cell xenograft model.  It is used to exam in vivo anti-tumor growth activity of a candidate drug. 3. Mouse LPS-induced cytokine production model.  It is used to exam in vivo anti-inflammation activities of a candidate drug. 4.Mouse ConA-induced liver injury model.  It is used to exam in vivo anti-inflammation activities of a candidate drug. 5.Rat Freund’s adjuvant arthritis model.  It is used to exam in vivo anti-inflammation activities of a candidate drug. 6.Rat carrageenan-induced paw edema model.  It is used to exam in vivo anti-inflammation activities of a candidate drug. 7.Rat cotton-ball granuloma model.  It is used to exam in vivo anti-inflammation activities of a candidate drug. 8.Mouse delayed type hypersensitivity (DTH) model.  It is used to exam in vivo anti-inflammation activities of a candidate drug. 9.Guinea pig OVA-induced asthma model.  It is used to exam in vivo anti-asthma activities of a candidate drug. 10.Mouse alloxan-induced type I diabetes model.  It is used to exam in vivo anti-diabetic activities of a candidate drug.